LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

34.92 0.66

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.77

Max

34.97

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5M -128M
Pardavimai	6.8M 11M
Pelnas, tenkantis vienai akcijai	-1.23
Pelno marža	-1,191.029
Darbuotojai	594
EBITDA	-18M -139M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+133.89% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-496M 3.9B
Ankstesnė atidarymo kaina	34.26
Ankstesnė uždarymo kaina	34.92

Naujienos nuotaikos

By Acuity

84%

16%

321 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-18 23:10; UTC

Karštos akcijos

Stocks to Watch: Agilysys, XP

2026-05-18 18:44; UTC

Pagrindinės rinkos jėgos

Claritev Shares Recover After Comments About DOJ

2026-05-18 23:55; UTC

Uždarbis

Review & Preview: Earnings' Last Gasp -- Barrons.com

2026-05-18 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-18 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-18 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

2026-05-18 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

2026-05-18 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

2026-05-18 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-18 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-18 20:25; UTC

Uždarbis

Correct: XP 1Q Total Client Assets BRL1.53T

2026-05-18 20:23; UTC

Uždarbis

XP 1Q Total Client Assets BRL1.53B

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Adj EPS BRL2.49 >XP

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Rev BRL4.73B >XP

2026-05-18 19:10; UTC

Rinkos pokalbiai

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

2026-05-18 19:00; UTC

Uždarbis

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

2026-05-18 18:52; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

2026-05-18 18:17; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

2026-05-18 17:22; UTC

Rinkos pokalbiai

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

2026-05-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

2026-05-18 16:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-18 16:57; UTC

Rinkos pokalbiai

Commodities Higher as Traders Want Physical Assets -- Market Talk

2026-05-18 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Doesn't Set Out Financial Details of Deal

2026-05-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

2026-05-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Buys Canada's Modern Group of Companies

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

133.89% į viršų

12 mėnesių prognozė

Vidutinis 86 USD 133.89%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

321 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.